Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) just unveiled an update.
Shandong Weigao Group Medical Polymer Company Limited reported a slight increase in revenue for the first half of 2025, reaching approximately RMB6.64 billion, a 0.1% rise from the previous year. However, the company’s net profit saw a decline of 9% to approximately RMB1.01 billion, attributed to increased costs and expenses. The board proposed an interim dividend of RMB0.0969 per share, pending shareholder approval. The financial results indicate challenges in maintaining profit margins despite stable revenue, reflecting the competitive pressures and cost management issues within the industry.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
More about Shandong Weigao Group Medical Polymer Co
Shandong Weigao Group Medical Polymer Company Limited is a joint stock limited company incorporated in the People’s Republic of China, operating in the medical polymer industry. The company focuses on producing medical devices and related products, catering to the healthcare sector.
Average Trading Volume: 12,326,945
Technical Sentiment Signal: Hold
Current Market Cap: HK$30.89B
For a thorough assessment of 1066 stock, go to TipRanks’ Stock Analysis page.